HTA for Orphan Medicinal Products (OMPs)
Dr Chris Skedgel
Director | OHE
Associated Masterclass: Innovation for Small Populations: What Should We Pay for?
Lecture duration: 19:32
- Are health conditions been salami-sliced to drive exceptionalism?
- Can evidence in support of Health Technology Assessment (HTA) submissions for OMPs meet the same standards as medicines for more common conditions?
- What is society willingness to prioritise treatments for rare conditions?